Biosimilars are entering the scene of intravitreal injections. Are they as safe and effective as their originator biologics? Are they truly interchangeable? What are the advantages and disadvantages? To answer these questions, Paolo Lanzetta, MD, speaks with Diego Fornasari, MD, PhD, Professor of Pharmacology, Director of the Postgraduate School in Clinical Pharmacology and Toxicology of the University of Milan.